An toàn và hoạt động kéo dài của protein phối hợp Fc của yếu tố VIII tái tổ hợp ở bệnh nhân hemophilia A
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mannucci, 2001, The haemophiliac: from royal genes to gene therapy., N Engl J Med, 344, 1773, 10.1056/NEJM200106073442307
Soucie, 2000, Mortality among males with hemophilia: relationship with source of medical care. The Hemophilia Surveillance System Project Investigators., Blood, 96, 437
Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia., New Engl J Med, 357, 535, 10.1056/NEJMoa067659
Aledort, 1994, A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group., J Intern Med, 236, 391, 10.1111/j.1365-2796.1994.tb00815.x
Petrini, 1991, Prophylaxis with factor concentrates in preventing hemophilic arthropathy., Am J Pediatr Hematol Oncol, 13, 280, 10.1097/00043426-199123000-00006
Aznar, 2000, The orthopaedic status of severe haemophiliacs in Spain., Haemophilia, 6, 170, 10.1046/j.1365-2516.2000.00397.x
Feldman, 2006, Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study., J Thromb Haemost, 4, 1228, 10.1111/j.1538-7836.2006.01953.x
Kreuz, 1998, When should prophylactic treatment in subjects with haemophilia A and B start? The German experience., Haemophilia, 4, 413, 10.1046/j.1365-2516.1998.440413.x
Liesner, 1996, The impact of prophylactic treatment on children with severe haemophilia., B J Haem, 92, 973, 10.1046/j.1365-2141.1996.420960.x
Ljung, 1998, Prophylactic treatment in Sweden: overtreatment or optimal model?, Haemophilia, 4, 409, 10.1046/j.1365-2516.1998.440409.x
Löfquist, 1997, Haemophilia prophylaxis in young subjects: a long-term follow-up., J Intern Med, 241, 395, 10.1046/j.1365-2796.1997.130135000.x
Nilsson, 1992, Twenty-five years's experience of prophylactic treatment in severe haemophilia A and B., J Int Med, 232, 25, 10.1111/j.1365-2796.1992.tb00546.x
Risebrough, 2008, Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A., Haemophilia, 14, 743, 10.1111/j.1365-2516.2008.01664.x
Van Den Berg, 2003, Comparing outcomes of different treatment regimens for severe haemophilia., Haemophilia, 9, 27, 10.1046/j.1365-2516.9.s1.10.x
Van Den Berg, 2004, Issues surrounding therapeutic choices for haemophilia patients., Haematologica, 89, 645
Blanchette, 2010, Prophylaxis in the haemophilia population., Haemophilia, 16, 181, 10.1111/j.1365-2516.2010.02318.x
Molho, 2000, Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France., Haemophilia, 6, 23, 10.1046/j.1365-2516.2000.00358.x
Coppola, 2008, Primary prophylaxis in children with haemophilia., Blood Transfus, 6, 4
Geraghty, 2006, Practice patterns in haemophilia A therapy: global progress towards optimal care., Haemophilia, 12, 75, 10.1111/j.1365-2516.2006.01189.x
Hacker, 2001, Barriers to compliance with prophylaxis therapy in haemophilia., Haemophilia, 7, 392, 10.1046/j.1365-2516.2001.00534.x
Lillicrap, 2010, Improvements in factor concentrates., Curr Opin Hematol, 17, 393, 10.1097/MOH.0b013e32833c06c6
Dumont, 2006, Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics., BioDrugs, 20, 151, 10.2165/00063030-200620030-00002
Dumont, 2012, Monomeric Fc fusion technology: an approach to create long lasting clotting factors., Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives, 10.1002/9783527644827.ch10
Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age., Nat Rev Immunol, 7, 715, 10.1038/nri2155
Lencer, 2005, A passionate kiss, then run: exocytosis and recycling of IgG by FcRn., Trends Cell Biol, 15, 5, 10.1016/j.tcb.2004.11.004
Huang, 2009, Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology., Curr Opin Biotechnol, 20, 692, 10.1016/j.copbio.2009.10.010
Schmidt, 2009, Fusion-proteins as biopharmaceuticals-applications and challenges., Curr Opin Drug Discov Devel, 12, 284
Dumont, 2012, Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs., Blood, 119, 3024, 10.1182/blood-2011-08-367813
Rosen, 1984, Assay of factor VIII:C with chromogenic substrate., Scand J Haematol Suppl, 40, 139, 10.1111/j.1600-0609.1984.tb02556.x
Lee, 1999, Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay., Thromb Haemost, 82, 1644
Mikaelsson, 2002, Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products., Semin Thromb Hemost, 28, 257, 10.1055/s-2002-32659
Stroobants, 2011, Differences between one-stage clotting and chromogenic FVIII assay results., J Thromb Haemost, 9
Lenting, 2007, Clearance mechanisms of von Willebrand factor and factor VIII., J Thromb Haemost, 5, 1353, 10.1111/j.1538-7836.2007.02572.x
Smith, 2010, Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium., Circulation, 121, 1382, 10.1161/CIRCULATIONAHA.109.869156
Terraube, 2010, Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance., Haemophilia, 16, 3, 10.1111/j.1365-2516.2009.02005.x
Mei, 2010, Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment., Blood, 116, 270, 10.1182/blood-2009-11-254755
Liu, 2008, Site-specific PEGylation of factor VIII (PEG-FVIII) preserves full clotting activity and extends therapeutic efficacy in hemophiliaA dogs [abstract]., Blood, 112, 10.1182/blood.V112.11.511.511
Agersoe, 2011, Prolonged effect of N8-GP in haemophilia A dogs supports less frequent dosing., J Thromb Haemost, 9, 115